- Home
- VATE vs BTAI Comparison
VATE vs BTAI Comparison
Compare VATE & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VATE
- BTAI
- Stock Information
- Founded
- VATE 1994
- BTAI 2017
- Country
- VATE United States
- BTAI United States
- Employees
- VATE N/A
- BTAI N/A
- Industry
- VATE Metal Fabrications
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- VATE Industrials
- BTAI Health Care
- Exchange
- VATE Nasdaq
- BTAI Nasdaq
- Market Cap
- VATE 65.1M
- BTAI 52.7M
- IPO Year
- VATE 1996
- BTAI 2018
- Fundamental
- Price
- VATE $5.69
- BTAI $3.79
- Analyst Decision
- VATE
- BTAI Strong Buy
- Analyst Count
- VATE 0
- BTAI 4
- Target Price
- VATE N/A
- BTAI $40.00
- AVG Volume (30 Days)
- VATE 22.6K
- BTAI 14.1M
- Earning Date
- VATE 11-05-2025
- BTAI 08-12-2025
- Dividend Yield
- VATE N/A
- BTAI N/A
- EPS Growth
- VATE N/A
- BTAI N/A
- EPS
- VATE N/A
- BTAI N/A
- Revenue
- VATE $995,000,000.00
- BTAI $868,000.00
- Revenue This Year
- VATE N/A
- BTAI N/A
- Revenue Next Year
- VATE N/A
- BTAI $597.46
- P/E Ratio
- VATE N/A
- BTAI N/A
- Revenue Growth
- VATE N/A
- BTAI N/A
- 52 Week Low
- VATE $3.25
- BTAI $1.17
- 52 Week High
- VATE $13.79
- BTAI $13.36
- Technical
- Relative Strength Index (RSI)
- VATE 58.49
- BTAI 48.02
- Support Level
- VATE $4.98
- BTAI $3.41
- Resistance Level
- VATE $5.72
- BTAI $4.20
- Average True Range (ATR)
- VATE 0.39
- BTAI 0.62
- MACD
- VATE 0.11
- BTAI -0.27
- Stochastic Oscillator
- VATE 97.27
- BTAI 11.05
About VATE INNOVATE Corp.
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting station across the United States.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.